Press Release

Ref: BHL/ STEX 21/ 2026-27 Date: July 20, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers 5th Floor, Exchange Plaza, Dalal Street Bandra Kurla Complex Bandra (East) Mumbai – 400 001 Mumbai-400051 Scrip Code: 539872 Symbol: BAJAJHCARE Sub: Press Release for the quarter ended June 30, 2026 Dear Sir/Madam, Please find enclosed the Press Release on the financial results of the Company for the quarter ended June 30, 2026. Kindly take the same on record. Thanking you. Yours faithfully, For and on behalf of Bajaj Healthcare Limited Monica Tanwar Company Secretary & Compliance Officer Encl: As above BAJAJ HEALTHCARE LIMITED Registered Office: 602-606, Bhoomi Velocity Infotech Park, Road No 23, Wagle Industrial Estate, Thane – 400 604 Website: www.bajajhealth.com Email: investors@bajajhealth.com CIN: L99999MH1993PLC072892 INVESTORRELEASE Bajaj Healthcare reports Q1 FY27 results Revenue Up 11.3% YoY; EBITDA Up 16.4% and PAT Up15.8% YoY Mumbai, 20th July 2026: Bajaj Healthcare Limited, one of the leading manufacturers of APIs, Intermediates and Formulations, announced its unaudited financial results for the quarter ended 30th June 2026. HighlightsofQ1FY27Results RevenuefromoperationsatRs.165.6Crore,up11.3%YoYand8.2%sequentially GrossprofitatRs.80.4Crore,up16.2%YoY;grossmarginexpandedto48.3%from46.2%inQ1FY26 EBITDAatRs.29.6Crore,up16.4%YoY;EBITDAmarginimprovedto17.8%from17.1%inQ1FY26 ProfitaftertaxatRs.13.7Crore,up15.8%YoY;PATmarginat8.3% BusinessSegmentPerformance API —Domestic Domestic API sales for the quarter were Rs. 92.3 Crore, up ~27% YoY from Rs. 72.6 Crore in Q1 FY26. The performancewasdrivenbystrongvolumegrowthacrosskeyproducts. API—Exports API export sales were Rs. 50.1 Crore for the quarter, as compared to Rs. 52.2 Crore in Q1 FY26 despite temporarydisruptionsarisingfromthegeopoliticalsituationinWestAsia Formulations Formulations revenue was Rs. 23.3 Crore for the quarter, compared to Rs. 24.1 Crore in Q1 FY26, reflecting a temporarymoderationduringtheperiod.TheCompanyexpectsperformancetonormalizeasFY27progresses. QuarterlyBusinessUpdates • Bajaj Healthcare became the first company in India to secure SEC recommendation for the manufacture and marketing of Cenobamate Tablets, a key milestone towards the commercialization of this next-generation anti-seizuremedicationdesignedforthetreatmentofpartial-onsetseizuresinadults. • During the quarter, the Company filed two CEP applications, taking the cumulative CEP filings to twelve. Of these,eightCEPshavebeenapproved,whilefourremainunderreview,furtherstrengtheningtheCompany's presenceintheregulatedEuropeanUnion(EU)andUnitedKingdom(UK)markets. ManagementCommentary CommentingontheResults,Mr.AnilJain–ManagingDirectorsaid, “We have commenced FY27 on a positive note, delivering healthy growth across key financial parameters. In Q1 FY27, revenue from operations grew 11.3% YoY, while improved product mix contributed to gross margin expansion to 48.3% from 46.2% in Q1 FY26. EBITDA increased 16.4% YoY, with EBITDA margin improving to 17.8%, reflecting the strength of our operational capabilities and disciplined execution. Profit after tax also recordedhealthygrowthof15.8%YoY. Our API division delivered a strong performance during the quarter, recording 14.0% YoY growth and 13.5% sequentialgrowth,drivenbyhealthydemandacrossthebusiness.Whiletheformulationssegmentwitnesseda marginaldeclineduringthequarter,weexpectthebusinessmixtograduallynormalizeasFY27progressesand marketconditionsimprove. We continue to strengthen the foundations for our next phase of growth. Our expanded state-of-the-art R&D Centre at Savli has now become operational, significantly enhancing our product development and process innovation capabilities. We are also progressing well towards the commercialization of Cenobamate Tablets following the regulatory milestone achieved during the quarter, reinforcing our commitment to building a differentiatedspecialtyportfolio. With a strong foundation and clear priorities, we remain committed to delivering sustainable growth and enhancinglong-termvalueforallourshareholders.” Financial Snapshot- Q1 FY27 (Rs. Mn) Particulars Q1FY27 Q1FY26 Y-o-Y Q4FY26 Q-o-Q FY26 API—Domestic 922.6 726.0 27.1% 868.5 6.2% 3,195.7 API—Exports 500.6 521.9 (4.1%) 385.4 29.9% 1,881.4 Formulations 233.1 240.5 (3.1%) 276.7 (15.8%) 1,033.2 RevenuefromOperations 1656.3 1,488.4 11.3% 1530.6 8.2% 6,110.3 GrossProfit 803.5 691.3 16.2% 745.0 7.8% 3,017.7 GrossMargin(%) 48.3% 46.2% 47.8% 48.8% EBITDA 295.6 253.9 16.4% 256.3 15.3% 1,119.5 EBITDAMargin(%) 17.8% 17.0% 16.7% 18.3% PAT* 137.0 118.3 15.8% 104.0 31.8% 490.1 PATMargin 8.3% 8.0% 6.8% 8.0% * PAT is before exceptional items EarningsCall The Company will host an earnings call at on 21st July, 2026, at 4:00 PM IST, where senior management will discuss the Company's performance and answer questions from participants. This call will be accessible throughanaudiodial-inandawebcast. Audio Conference Universal Dial In: +91 22 6280 1550 / +91 22 7115 8378 International Toll Free: Hong Kong : 800964448, UK : 08081011573, Singapore : 8001012045, USA : 18667462133 Pre-registration Click Here Webcast Details will be provided through the Company's website, www.bajajhealth.com Toparticipateintheaudiocall,pleasedialthenumbersprovidedfivetotenminutesaheadofthescheduled starttime.Atranscriptoftheevent willbemadeavailableontheCompany'swebsitefollowingthecall. Disclaimer This presentation contains forward-looking statements based on current expectations, assumptions, and estimates. Actual results may differ materially due to various risks and uncertainties. The Company undertakes no obligation to update or revise these statements, except as required under applicable laws and regulations. AboutBajajHealthcareLimited Bajaj Healthcare Limited is a leading manufacturer of APIs, Intermediates and Formulations. Established in 1993,ithasbuiltastrongreputationfordeliveringhighqualitypharmaceuticalproducts,nutraceuticalsacross various therapies. The Company operates state-of-the-art manufacturing facilities that are designed to meet the requirements of both regulated and emerging markets. With a strong global presence, BHL serves customersacrossEurope,USA,Australia,MiddleEast,andSouthAmerica. Contacts Company: Investor Relations Advisors: MUFGIntimeIndiaPrivateLimited Mr.RohanParekh- CFO Ms.PrachiAmbre—prachi.ambre@in.mpms.mufg.com Email:investors@bajajhealth.com Mr.IrfanRaeen—irfan.raeen@in.mpms.mufg.com